In DeLLphi-305, IMDELLTRA–durvalumab significantly extended median overall survival to 21.1 months versus 12.7 months with durvalumab alone, a gain of more than eight months.

Interim Phase 3 results from Amgen show IMDELLTRA plus IMFINZI cutting the risk of death by 58% as first‑line maintenance for extensive-stage small cell lung cancer, with a hazard ratio of 0.42 at roughly 16 months follow‑up (P<0.001).

Additional data reinforce IMDELLTRA’s activity across ES-SCLC, including DeLLphi-303 (first-line maintenance) with median OS of 37.9 months and 58.1% two‑year survival, and DeLLphi-304 showing sustained benefit versus chemotherapy in previously treated ES-SCLC.

At the conference, discussions on mRNA vaccines highlighted trust and misinformation, with Dana-Farber’s Toni Choueiri noting public skepticism could hinder adoption, while Moderna’s Stéphane Bancel argued cancer applications could shift perceptions.

ESMO 2026 presentations and NEJM publication mark a potential watershed moment for SCLC treatment, as leaders from Amgen and AZ frame the results as transformative.

Safety profiles include common CRS and neurologic toxicity, with guidance on step‑up dosing and post‑infusion monitoring.

Important safety notes carry boxed warnings for CRS and ICANS (neurologic toxicity), with detailed monitoring and management recommendations throughout the dosing schedule.

The overall narrative at ESMO captures high‑profile trial results and debates, including personalized cancer vaccines, mRNA perceptions, and combination therapies in lung and bladder cancers, with NEJM publications and questions about survival benefits and sequencing.

Kate Brenan’s patient perspective illustrates perceived real‑world impact and optimism for earlier use of Imdelltra in regimens.

The addressable ES-SCLC patient population could grow substantially if benefits extend to second‑line and earlier stages, with current second‑line labeling covering about 13,000 U.S. patients and potential expansion to 35,000–40,000 overall.

Amgen emphasizes IMDELLTRA’s potential to transform disease management and make ES-SCLC more controllable over time.

Imdelltra’s success positions it as a backbone therapy for ES-SCLC and spurs interest in DLL3‑targeted strategies, including competitors like Zai Lab’s zoci and other DLL3/B7‑H3 approaches.